Literature DB >> 31119300

Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease.

Hyejin Kim1, Oliver Worsley2, Edwin Yang3,4, Rikky Wenang Purbojati5, Ai Leng Liang3, Wilson Tan2, Daniela I Drautz Moses5, Septian Hartono6, Vanessa Fan7, Tony Kiat Hon Lim8, Stephan C Schuster5, Roger Sy Foo9,10, Pierce Kah Hoe Chow11,12,13, Sven Pettersson14,15,16,17.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disease that is thought to be reversible by changing the diet. To examine the impact of dietary changes on progression and cure of NAFLD, we fed mice a high-fat diet (HFD) or high-fructose diet (HFrD) for 9 weeks, followed by an additional 9 weeks, where mice were given normal chow diet. As predicted, the diet-induced NAFLD elicited changes in glucose tolerance, serum cholesterol, and triglyceride levels in both diet groups. Moreover, the diet-induced NAFLD phenotype was reversed, as measured by the recovery of glucose intolerance and high cholesterol levels when mice were given normal chow diet. However, surprisingly, the elevated serum triglyceride levels persisted. Metagenomic analysis revealed dietary-induced changes of microbiome composition, some of which remained altered even after reversing the diet to normal chow, as illustrated by species of the Odoribacter genus. Genome-wide DNA methylation analysis revealed a "priming effect" through changes in DNA methylation in key liver genes. For example, the lipid-regulating gene Apoa4 remained hypomethylated in both groups even after introduction to normal chow diet. Our results support that dietary change, in part, reverses the NAFLD phenotype. However, some diet-induced effects remain, such as changes in microbiome composition, elevated serum triglyceride levels, and hypomethylation of key liver genes. While the results are correlative in nature, it is tempting to speculate that the dietary-induced changes in microbiome composition may in part contribute to the persistent epigenetic modifications in the liver.

Entities:  

Keywords:  DNA methylation; Epigenetics; Gut microbiome; High-fat diet; NAFLD

Mesh:

Substances:

Year:  2019        PMID: 31119300     DOI: 10.1007/s00018-019-03114-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  44 in total

1.  Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.

Authors:  Na Jiao; Susan S Baker; Adrian Chapa-Rodriguez; Wensheng Liu; Colleen A Nugent; Maria Tsompana; Lucy Mastrandrea; Michael J Buck; Robert D Baker; Robert J Genco; Ruixin Zhu; Lixin Zhu
Journal:  Gut       Date:  2017-08-03       Impact factor: 23.059

2.  Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter.

Authors:  Silvia Sookoian; Maria Soledad Rosselli; Carolina Gemma; Adriana L Burgueño; Tomas Fernández Gianotti; Gustavo O Castaño; Carlos J Pirola
Journal:  Hepatology       Date:  2010-10-01       Impact factor: 17.425

3.  Multipoint Dixon technique for water and fat proton and susceptibility imaging.

Authors:  G H Glover
Journal:  J Magn Reson Imaging       Date:  1991 Sep-Oct       Impact factor: 4.813

4.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice.

Authors:  Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

5.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

6.  Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota.

Authors:  Chih-Jung Chang; Chuan-Sheng Lin; Chia-Chen Lu; Jan Martel; Yun-Fei Ko; David M Ojcius; Shun-Fu Tseng; Tsung-Ru Wu; Yi-Yuan Margaret Chen; John D Young; Hsin-Chih Lai
Journal:  Nat Commun       Date:  2015-06-23       Impact factor: 14.919

7.  Gut microbiota as an epigenetic regulator: pilot study based on whole-genome methylation analysis.

Authors:  Himanshu Kumar; Riikka Lund; Asta Laiho; Krista Lundelin; Ruth E Ley; Erika Isolauri; Seppo Salminen
Journal:  mBio       Date:  2014-12-16       Impact factor: 7.867

8.  Genome-wide hepatic DNA methylation changes in high-fat diet-induced obese mice.

Authors:  AhRam Yoon; Stephanie A Tammen; Soyoung Park; Sung Nim Han; Sang-Woon Choi
Journal:  Nutr Res Pract       Date:  2017-03-15       Impact factor: 1.926

9.  Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.

Authors:  Sonia Michail; Malinda Lin; Mark R Frey; Rob Fanter; Oleg Paliy; Brian Hilbush; Nicholas V Reo
Journal:  FEMS Microbiol Ecol       Date:  2014-12-05       Impact factor: 4.519

Review 10.  Gut Microbiota and Host Reaction in Liver Diseases.

Authors:  Hiroshi Fukui
Journal:  Microorganisms       Date:  2015-10-28
View more
  9 in total

Review 1.  Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.

Authors:  Johanna K DiStefano
Journal:  Cell Mol Life Sci       Date:  2020-06       Impact factor: 9.261

2.  Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion.

Authors:  Alessio Ardizzone; Marika Lanza; Giovanna Casili; Michela Campolo; Irene Paterniti; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  Nutrients       Date:  2022-05-27       Impact factor: 6.706

3.  Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Authors:  Volodymyr P Tryndyak; Rose A Willett; Mark I Avigan; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  Epigenetics       Date:  2022-03-24       Impact factor: 4.861

4.  Integrated analysis of the methylome and transcriptome of chickens with fatty liver hemorrhagic syndrome.

Authors:  Xiaodong Tan; Ranran Liu; Yonghong Zhang; Xicai Wang; Jie Wang; Hailong Wang; Guiping Zhao; Maiqing Zheng; Jie Wen
Journal:  BMC Genomics       Date:  2021-01-06       Impact factor: 3.969

5.  Prolonged Changes in Hepatic Mitochondrial Activity and Insulin Sensitivity by High Fructose Intake in Adolescent Rats.

Authors:  Arianna Mazzoli; Cristina Gatto; Raffaella Crescenzo; Luisa Cigliano; Susanna Iossa
Journal:  Nutrients       Date:  2021-04-19       Impact factor: 5.717

6.  Tissue-specific reprogramming of host tRNA transcriptome by the microbiome.

Authors:  Jia Huang; Wenjun Chen; Fan Zhou; Zhichang Pang; Luoluo Wang; Tao Pan; Xiaoyun Wang
Journal:  Genome Res       Date:  2021-04-15       Impact factor: 9.043

7.  Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus.

Authors:  Weijia Han; Chunyang Huang; Yali Ji; Ling Zhou; Jinjun Chen; Jinlin Hou
Journal:  Front Med (Lausanne)       Date:  2021-12-21

Review 8.  Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Eunju Park; Jin-Ju Jeong; Sung-Min Won; Satya Priya Sharma; Yoseph Asmelash Gebru; Raja Ganesan; Haripriya Gupta; Ki Tae Suk; Dong Joon Kim
Journal:  Cells       Date:  2021-10-02       Impact factor: 6.600

Review 9.  A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma.

Authors:  Brittany Dewdney; Alexandra Roberts; Liang Qiao; Jacob George; Lionel Hebbard
Journal:  Biomolecules       Date:  2020-03-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.